LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.63M | 10.56M | 9.02M | 7.42M | 6.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.63M | 10.56M | 9.02M | 7.42M | 6.57M |
| Cost of Revenue | 8.71M | 8.17M | 7.23M | 6.20M | 6.33M |
| Gross Profit | 2.92M | 2.39M | 1.79M | 1.22M | 237.10K |
| SG&A Expenses | 2.77M | 2.49M | 2.19M | 3.51M | 3.90M |
| Depreciation & Amortization | 25.70K | 24.60K | 24.60K | 24.60K | 24.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.45M | 10.63M | 9.46M | 9.78M | 10.58M |
| Operating Income | 182.40K | -68.60K | -447.90K | -2.35M | -4.01M |
| Income Before Tax | -1.22M | -1.50M | -1.90M | -5.68M | -7.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.22 | -1.50 | -1.90 | -5.68 | -7.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.22M | -1.50M | -1.90M | -5.68M | -7.56M |
| EBIT | 182.40K | -68.60K | -447.90K | -2.35M | -4.01M |
| EBITDA | 956.70K | 704.90K | 287.80K | -1.68M | -3.32M |
| EPS Basic | -0.01 | -0.02 | -0.02 | -0.08 | -0.10 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.03 | -0.05 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.08 | -0.10 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 387.99M | 355.34M | 332.00M | 317.45M | 306.85M |
| Average Diluted Shares Outstanding | 388.30M | 355.46M | 332.00M | 317.45M | 306.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
